Metabolic Status and Resistin in Chronic Schizophrenia Over a 2-Year Period With Continuous Atypical Antipsychotics

Therapeutic Advances in Psychopharmacology
doi 10.1177/2045125315596697
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Lipidomics Reveals Early Metabolic Changes in Subjects With Schizophrenia: Effects of Atypical Antipsychotics

PLoS ONE
Multidisciplinary
2013English

Metabolic Effect of Atypical Antipsychotics

Kansas Journal of Medicine
2010English

Metabolic Effects of Treatment With Atypical Antipsychotics

Journal of Clinical Psychiatry
MedicinePsychiatryMental Health
2004English

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2017English

Antipsychotic Monotherapy and Polypharmacy in the Naturalistic Treatment of Schizophrenia With Atypical Antipsychotics

BMC Psychiatry
PsychiatryMental Health
2005English

Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil

Applied Health Economics and Health Policy
MedicineHealth PolicyEconomicsEconometrics
2018English

Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics

American Journal of Psychiatry
PsychiatryMental Health
2003English

Erratum To: Suicidality and Second Generation Antipsychotics in Schizophrenia Patients: A Case-Controlled Retrospective Study During a 5-Year Period

Psychopharmacology
Pharmacology
2010English

Atypical Antipsychotics

PharmacoEconomics & Outcomes News
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy